Authors

Latest:

Dr. Goldfischer on Integrated Medical Groups

Evan R. Goldfischer, MD, MBA, FACS, director of the Research Department at Premier Medical Group of the Hudson Valley, discusses the benefits of integrated medical groups.

Evan W. Alley, MD, PhD

Latest:

Dr. Evan Alley on KEYNOTE-028 Trial Results in Mesothelioma

Evan W. Alley, MD, PhD, discusses the results from the phase Ib KEYNOTE-028 trial on a cohort of patients with malignant pleural mesothelioma.

Evan Wu, MD

Latest:

Metastatic Cancer Is a Chronic Condition

Advancements in targeted therapy and immunotherapy have led to a rapidly increasing number of patients with metastatic cancer becoming patients with chronic cancer.

Evan Y. Yu, MD

Evan Y. Yu, MD, is section head of Medical Oncology and a professor in the Clinical Research Division at the Fred Hutchinson Cancer Center; medical director of Clinical Research Support at Fred Hutchinson/University of Washington (UW)/Seattle Children’s Cancer Consortium; and the assistant fellowship director and a professor in the Division of Hematology and Oncology at UW Medicine

Latest:

Dr Yu on Factors Influencing PARP Inhibitor Selection in mCRPC

Evan Ya-Wen Yu, MD, discusses the PARP inhibitors that are available for the treatment of patients with mCRPC.

Evan Y. Yu, MD, Fred Hutchinson Cancer Research Center

Latest:

Overview of Improvements in Prostate Cancer Management

Broad discussion on the evolution of care in prostate cancer from both the therapeutic and imaging standpoints.

Evan Y. Yu, MD, Seattle Cancer Care

Evan Y. Yu, MD, Seattle Cancer CareÂ Â

Evan Yu, MD, University of Washington

Evangelia Razis, MD, PhD

Latest:

Dr. Razis on the Significance of TERT in the Presence of NF1 in GBM

Evangelia Razis, MD, PhD, medical oncologist, Hygeia Hospital, Athens, Greece, discusses the significance of TERT mutations in the presence of NF1 mutations in patients with glioblastoma (GBM).

Evanthia Roussos Torres, MD

Latest:

Dr. Roussos Torres on the Importance of Preclinical Models in HER2+ Breast Cancer

Evanthia Roussos Torres, MD, oncology fellow, Johns Hopkins University School of Medicine, discusses the importance of preclinical models in HER2-positive breast cancer.

Everett E. Vokes, MD

Latest:

Dr. Vokes Discusses Unanswered Questions from the PACIFIC Trial in NSCLC

Everett E. Vokes, MD, discusses unanswered questions from the phase III PACIFIC trial in stage III non–small cell lung cancer.

Everett E. Vokes, MD, University of Chicago Medicine

Everett Vokes, MD

Latest:

Preview of ASCO 2022: Dr Everett Vokes

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Everett Vokes, MD, University of Chicago Medicine

Eytan M. Stein, MD

Eytan M. Stein, MD, is the Chief of the Leukemia Service, Associate Attending Physician, Clinical Investigator, and Director of the Program for Drug Development

Latest:

Dr Stein on the Emerging Role of Menin Inhibitors in Frontline Combinations for AML

Eytan M. Stein, MD, discusses the emerging role of menin inhibitors such as revumenib in combination treatment strategies for AML.

Eytan Stein, MD

Latest:

Dr Stein on the Efficacy of Revumenib in KMT2A+ R/R Acute Leukemia

Eytan M. Stein, MD, discusses efficacy findings from the phase 1/2 AUGMENT-101 study of revumenib in KMT2A-rearranged relapsed/refractory acute leukemia.

Ezra Cohen, MD

Latest:

Dr. Cohen on Future Research Directions in Head and Neck Cancer

Ezra Cohen, MD, FRCPSC, FASCO, discusses future research directions for the treatment of patients with head and neck cancer.

Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego

Latest:

Sequencing Throughout Multiple Lines of Therapy in RR DTC

Before closing out their discussion on RR DTC management, panelists consider the advent of sequencing through multiple lines of therapy.

Ezra Cohen, MD, Moores Cancer Center

Ezra Cohen, MD, UC San Diego Moores Cancer Center